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fibrosis progression in non-alcoholic fatty liver
disease and alcoholic liver disease
Müjdat Zeybel1, Timothy Hardy1, Stuart M Robinson1, Christopher Fox1, Quentin M Anstee1, Thomas Ness2,
Steven Masson1, John C Mathers1, Jeremy French1, Steve White1 and Jelena Mann1*Abstract
Background: Chronic liver injury can lead to the development of liver fibrosis and cirrhosis but only in a minority of
patients. Currently, it is not clear which factors determine progression to fibrosis. We investigated whether DNA\methylation
profile as determined by pyrosequencing can distinguish patients with mild from those with advanced/severe fibrosis in
non-alcoholic liver disease (NAFLD) and alcoholic liver disease (ALD). To this end, paraffin-embedded liver biopsies were
collected from patients with biopsy-proven NAFLD or ALD, as well as paraffin-embedded normal liver resections, genomic
DNA isolated, bisulfite converted and pyrosequencing assays used to quantify DNA methylation at specific CpGs within
PPARα, PPARα, TGFβ1, Collagen 1A1 and PDGFα genes. Furthermore, we assessed the impact of age, gender and anatomical
location within the liver on patterns of DNA methylation in the same panel of genes.
Results: DNA methylation at specific CpGs within genes known to affect fibrogenesis distinguishes between patients
with mild from those with severe fibrosis in both NAFLD and ALD, although same CpGs are not equally represented in
both etiologies. In normal liver, age, gender or anatomical location had no significant impact on DNA methylation
patterns in the liver.
Conclusions: DNA methylation status at specific CpGs may be useful as part of a wider set of patient data for predicting
progression to liver fibrosis.
Keywords: NAFLD, ALD, Epigenetics, DNA methylation, PyrosequencingBackground
Chronic liver injury of any aetiology can lead to develop-
ment of liver fibrosis and ultimately cirrhosis [1]. Pro-
gression of fibrotic liver disease towards cirrhosis is not
linear but rather dynamic and highly variable between
individuals. This individual variability is modulated by
age, gender and genetic predisposition, which interact
with an array of environmental factors such as poor diet,
alcohol consumption and smoking to determine progres-
sion [2]. Progressive fibrosis and its end stage, cirrhosis,
tend to develop very slowly over a period of 20 years or
even longer [2]. However, not everyone who suffers
chronic liver injury will develop fibrosis or cirrhosis;* Correspondence: Jelena.Mann@ncl.ac.uk
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unless otherwise stated.only a minority of patients reach end-stage liver disease
[3,4]. Despite increasing knowledge of the processes
underpinning liver disease progression, it is still not pos-
sible to predict which patients will progress and which
will experience minimal fibrogenesis. This is an import-
ant challenge as lack of predictability makes prognosis
and patient stratification difficult and limits the rational
basis for management options.
Epigenetic processes play a prominent role in a num-
ber of complex diseases and may mediate the effects of
environmental factors including diet and alcohol [5,6].
This plasticity of epigenetic marks and molecules in re-
sponse to environmental and genotypic influences may
help explain inter-individual differences in responses [7].
Combinations of histone modifications, non-coding
RNAs and DNA methylation, in conjunction with tran-
scription factors, ultimately instruct the expression ofThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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sible and likely that pre-existing epigenetic marks may at
least in part instruct liver disease progression.
DNA methylation occurs at the cytosine base within a
cytosine-guanine dinucleotide (often referred to as CpG)
where DNA methyltransferase catalyses transfer of a me-
thyl group to the fifth carbon atom within the cytosine
ring to form 5-methylcytosine [9]. In many cases, higher
levels of DNA methylation around gene promoters cor-
relate with low or no transcription [10]. In humans, the
DNA methylation levels at a particular promoter within a
given cell type is likely to be very similar; however, there are
significant differences in levels of DNA methylation at de-
fined loci between different cell types and tissues. DNA
methylation plays an important role in numerous processes,
including genomic imprinting, cellular differentiation,
embryonic development, X-chromosome inactivation and
chromosome stability. Given its importance in regulation
of transcription/gene expression and, therefore, in cellular
differentiation, errors in DNA methylation impact on
multiple disease processes, including cancer [11,12].
Although DNA methylation analysis has not been used
to predict liver injury outcome, there have been several
studies indicating that changes in locus-specific DNA
methylation can affect insulin resistance and severity of
non-alcoholic fatty liver disease (NAFLD), as well as pre-
dict the response to a low-calorie diet [13-16]. Given these
precedents in patient studies, it is conceivable that altered
DNA methylation levels may also instruct differential gene
expression in development of liver fibrosis. Specifically, we
hypothesised that altered patterns of DNA methylation in
pro-fibrogenic as well as anti-fibrogenic genes within hep-
atic cellular compartments in some individuals will im-
pede liver disease progression. In particular, genes known
to be involved in specific signalling pathways that enhance
the likelihood of progression of chronic liver injury, in-
cluding TGFβ1, Collagen 1A1 and PDGFα may be more
highly methylated in individuals that remain fibrosis free,
whereas anti-fibrogenic genes such as PPARα and PPARδ
may have higher DNA methylation levels in individuals ex-
periencing fast progress towards severe fibrosis. Ascertaining
DNA methylation in patients is possible only via sampling
of liver tissue, either by percutaneous liver biopsy, by direct
sampling of the organ during liver resection or by sampling
of freshly explanted, cirrhotic liver.
Liver biopsy remains the gold standard for assessment
of aetiology and fibrosis staging, although there are draw-
backs to this method including its inherent invasiveness
and significant sampling variability [17]. In this study, we
utilise liver biopsy material from mild and severe NAFLD
cohorts to assess whether DNA methylation pattern at
specific CpGs within pro-fibrogenic and anti-fibrogenic
genes can be used as a prognostic indicator of fibrosis pro-
gression. Furthermore, we extend these studies into severeALD, which are compared with normal liver. Finally, we
use multiple sampling across the same normal liver to as-
certain whether DNA methylation patterns are consistent/
stable across the organ and what changes, if any, might be
associated with age and gender.
Results and discussion
DNA methylation in mild versus severe NAFLD cohort
shows significant differences across several CpGs within
fibrosis-related genes
We obtained liver tissue from paraffin-embedded percu-
taneous needle biopsies carried out in eight NAFLD pa-
tients with minimal fibrosis and nine NAFLD patients
with advanced fibrosis (Tables 1 and 2). The NAFLD co-
hort was entirely male and the clinical laboratory charac-
teristics, other than ALT and triglycerides, were not
significantly different between the two groups (Tables 1
and 2) The difference in age did not reach statistical sig-
nificance, probably due to lack of statistical power.
Histological scoring of all samples was conducted by
two expert clinical pathologists. Patients with advanced
fibrosis NAFLD exhibited significantly more hepatocyte
ballooning and portal inflammation, consistent with the
presence of a more active steatohepatitis than those in
the mild NAFLD fibrosis group (Table 1).
Since higher DNA methylation is associated with gene
silencing, we sought to determine whether pro-fibrogenic
genes (TGFβ1, Collagen1A1 and PDGFδ) are less methyl-
ated in severe NAFLD whereas anti-fibrogenic genes (such
as PPARα and PPARδ) might bear higher DNA methyla-
tion in the same cohort. To determine if NAFLD-fibrosis
severity influences DNA methylation of specific fibrosis-
related genes, we isolated genomic DNA from percutan-
eous needle biopsies in all patients and quantified
methylation of specific CpGs within gene regulatory re-
gions of PPARα, PPARδ, TGFβ1, Collagen1A1 and PDGFα
as shown in Figure 1. Using pre-validated pyrosequencing
assays, we show that out of three CpGs measured, the
CpG3 in the target region of the PPARα promoter had sig-
nificantly higher DNA methylation in the severe NAFLD
group (10.9% DNA methylation) when compared to the
mild NAFLD patients (1.1%, Figure 1A). Similarly, CpG2
within the target region of the PPARδ promoter showed
statistically higher DNA methylation in the severe group
(Figure 1B). However, the opposite effect was observed for
the TGFβ1 gene, where there was lower DNA methylation
in those with severe disease (Figure 1C). Although we ob-
served a trend towards lower DNA methylation in CpG1
within the target region of Collagen1A1, this was not sta-
tistically significant (Figure 1D). Methylation of CpG3 in
the PDGFα promoter in the severe NAFLD group was
only half of that in the mild disease group (11.5% and
21.2%, respectively, Figure 1E). Taken together, these data
show that DNA methylation at specific CpGs differs
Table 1 Comparison of the clinical and demographic factors between mild and severe NALFD cohorts
NAFLD (mild fibrosis) F0 to F2 (n = 8) NAFLD (severe fibrosis) F3 to F4 (n = 9) Statistical significance
Age, mean (95% CI) 51.88 (40.43 to 63.32) 60.56 (54.50 to 66.61) ns
Male sex (%) 8 (100%) 9 (100%) ns
AST (IU/L) (95% CI) 45.38 (27.69 to 63.06) 43.86 (32.92 to 54.79) ns
ALT (IU/L) (95% CI) 79.75 (39.51 to 120) 45.56 (30.5 to 60.96) P = 0.04
BMI (kg/m2) 35 (30 to 43.2) 36 (30 to 46) ns
Cholesterol (mmol/L) 5.2 (3 to 7) 4.0 (2.7 to 5.5) ns
Triglycerides (mmol/L) 5.8 (2 to 12.5) 2.2 (0.8 to 4.7) P = 0.01
HDL cholesterol (mmol/L) 0.9 (0.6 to 1.2) 1.1 (0.7 to 1.6) ns
LDL cholesterol (mmol/L) 3.8 (2.1 to 6.2) 2.6 (1.5 to 3.9) ns
Total/HDL ratio 6.1 (3.3 to 9.5) 3.9 (2.1 to 6.1) ns
Steatosis
0 (<5%) - 1
1 (5% to 33%) 1 8
2 (33% to 66%) 5 -
3 (66%<) 2
Inflammation
0 2 1
1 4 3
2 2 5
3
Ballooning
0 1 2
1 7 3
2 - 4
Fibrosis
0 - -
1 7 -
2 2 -
3 - 4
4 - 5
Zeybel et al. Clinical Epigenetics  (2015) 7:25 Page 3 of 11according to fibrosis stage and we hypothesise that this
may be linked with alterations in expression of genes
known to regulate fibrosis progression. Furthermore, these
differences suggest that epigenetic remodelling in liver fi-
brosis may have clinical relevance.
DNA methylation in normal human liver versus ALD
cohort shows significant differences across several CpGs
within fibrosis-related genes
We were next interested to learn whether the differences
observed in mild and severe NAFLD were specific to the
aetiology of liver disease or due simply to the presence
of fibrosis in the liver. To that end, we compared DNA
methylation signatures at the CpGs described above in a
second liver disease, ALD. Normal human liver had no
signs of fibrosis whereas all ALD samples were graded ascirrhotic. The ALD cohort included two samples from
end-stage ALD, obtained from freshly explanted organ.
The normal human liver cohort (17 patients) had a
mean age of 63.3 ± 8.4 years and a 10/7 split of male to
female, whereas the ten ALD patients had a younger
mean age of 46.3 ± 10.08 years with a 6/4 male to female
split (see Table 3). Patients in the normal human liver
cohort were taking significantly more anti-hypertensive
medication than the ALD cohort (Table 4). The patients
were undergoing surgery for major liver resection due to
the presence of primary or secondary tumour. Details of
resection indication, pre-operative chemotherapy regime,
presence of other comorbidities, medication and import-
antly background liver histology are listed in Table 5.
We observed higher DNA methylation for all three
CpGs at the PPARα promoter in ALD tissue (Figure 2A).
Table 2 Comparison of comorbidity data between mild and severe NAFLD cohorts
NAFLD (mild fibrosis)
F0 to F2 (n = 8)
NAFLD (severe fibrosis)
F3 to F4 (n = 9)
Statistical
significance
Hypertension (N, %) 5 (62.5%) 4 (44%) ns
Any hypertensive medication (N, %) 5 (62.5%) 6 (66%) ns
T2DM (N, %) 8 (100%) 8 (100%) ns
Insulin treated (N, %) 3 (37.5%) 3 (33.3%) ns
Oral medication treated (N, %) 3 (37.5%) 7 (77.7%) ns
Diet treated (N, %) 2 (25%) 1 (11.1%) ns
Cardiovascular disease (N, %) 2 (25%) 2 (22.2%) ns
Dyslipidemia treated with lipid
lowering agents (N, %)
4 (50%) 6 (66.6%) ns
1 Med (N, %) 3 (37.5%) 6 (66.6%) ns
>2 Meds (N, %) 1 (12.5%) 0 (0%) ns
Zeybel et al. Clinical Epigenetics  (2015) 7:25 Page 4 of 11Although these differences were statistically significant,
the absolute levels of DNA methylation were overall lower
than those in the severe NAFLD tissue (Figures 1A and
2A). In the PPARδ promoter, CpG3 in the target sequence
had significantly higher methylation in ALD when com-
pared with normal human liver (Figure 2B). Surprisingly,
methylation of CpG2 in TGFβ1 showed increased methy-
lation in the ALD group (Figure 2C). Collagen1A1 CpG2
was less methylated in ALD (Figure 2D), whereas noFigure 1 DNA methylation at particular CG dinucleotides within the hu
exon 1 (C), collagen 1A1 intron 1 (D) and PDGFα gene promoter (E) in li
severe (3 to 4 Kleiner score) NAFLD was determined by pyrosequencing
methylated CGs are shown in the schematic drawing above the graphs. Di
represent mean values ± standard error of the mean (SEM). *P < 0.05; **P <methylation differences were detected in any CpGs within
PDGFα (Figure 2E).
DNA methylation in normal human liver - age and gender
impacts
A liver biopsy represents around 50,000th of the entire
organ, and it is well known that biopsy results can show
significant variability of up to 40% for fibrosis staging. In
the context of this study, it was important to establishman PPARα gene promoter (A), PPARδ gene promoter (B), TGFβ1
ver biopsy tissues from patients with mild (0 to 2 Kleiner score) or
. The relative position and surrounding sequence of the differentially
fferences are expressed as percentage of DNA methylation. Error bars
0.01.
Table 3 Comparison of the clinical and demographic factors between normal human liver and ALD cohort
Normal human liver (n = 17) ALD (cirrhosis) (n = 10)
Age, mean (95% CI) 63.31 (67.94 to 54.71) 46.30 (57.27 to 39.09) P = 0.002
Male sex (%) 10 (58%) 7 (70%) ns
ALT (IU/L) (95% CI) - 49 (32 to 69)
BMI (kg/m2) - 24.2 (19 to 32.5)
Cholesterol (mmol/L) - 4.7 (2.0 to 8.7)
Triglycerides (mmol/L) - 1.9 (0.9 to 3.6)
HDL cholesterol (mmol/L) - -
LDL cholesterol (mmol/L) - 2.9 (1.4 to 5.3)
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genetic patterns throughout the organ or whether epigen-
etic signatures differ in different parts of the liver. To this
end, we obtained from three to nine samples of normal hu-
man liver from 17 patients as outlined in the previous sec-
tion. The samples were minimally 3 cm and maximally 25
cm apart. We isolated genomic DNA from all samples, car-
ried out bisulphite conversion then quantified methylation
at specific CpGs within regulatory regions of PPARα
(CpG3), PPARδ (CpG2), TGFβ1 (CpG2) and PDGFα
(CpG3) genes that showed differential methylation in either
the NAFLD and/or ALD cohort (Figure 3). Each dot along
the same vertical axis represents a unique sample from
the same patient (Figure 3A-D). The 17 patients have
been ranked according to age from youngest to oldest
(Figure 3A-D) with females in red and males in blue. The
same patients are also listed in same age order in Table 5,
simply labelled 1 through to 17. The results show that, for
all target genes, intra-patient variability in DNA methyla-
tion was relatively low for samples taken a various locations
within the organ. For example, DNA methylation at PPARα
CpG3 shows around 2% intra-patient/ intra-hepatic vari-
ability (Figure 3A) with similar variability for PPARδ CpG2
(Figure 3B) and TGFβ1 CpG2 (Figure 3C) while PDGFα
CpG3 has a slightly higher intra-patient/intra-hepatic vari-
ability of just under 5% (Figure 3D). In summary, neither
age nor gender appeared to affect DNA methylation pat-
terns in the selected gene panel in human liver.Table 4 Comparison of comorbidity data between normal hu
Normal human
Hypertension (N, %) 4 (23.5%)
Any hypertensive medication (N, %) 4 (23.5%)
T2DM (N, %) 0 (0%)
Diet treated 0 (0%)
Cardiovascular disease (N, %) 2 (11.7%)
Dyslipidemia treated with lipid lowering agents (N, %) 3 (17.6%)
1 Med 3 (17.6%)
>2 Meds 0 (0%)Conclusions
We report a targeted DNA methylation study in which
we quantified methylation of specific CpGs at defined
loci across five genes involved in the regulation of fibro-
genesis. Our cohorts consisted of NAFLD patients with
mild and advanced fibrosis, cirrhotic ALD patients and
normal human livers. The results were generated from
pyrosequencing assays carried out on genomic DNA iso-
lated from percutaneous liver biopsy material in all of
the NAFLD and eight ALD patients, with the remainder
of ALD and all normal human liver samples being col-
lected during transplantation and surgical resection,
respectively.
Approximately half of all human gene promoters have
dense clustering of CpG dinucleotides, known as CpG
islands. As a general rule, hypermethylation of CpG
islands is associated with gene repression, whereas hypo-
methylation is permissive to transcription [18]. As such,
we hypothesised that genes known to drive fibrogenesis,
including TGFβ1, Collagen 1A1 and PDGFα, might be
more highly methylated and consequently be expressed at
a lower level in patients that do not progress to severe fi-
brosis but rather retain a mild phenotype despite on-going
liver injury. Conversely, anti-fibrogenic genes PPARα and
PPARδ would be expected to have less DNA methylation
in the non-progressor/normal human liver group. In con-
firmation of our hypothesis, we show that specific CpGs
within TGFβ1 (CpG2) and PDGFα (CpG3) (Figure 1B,E)man liver and ALD cohort
liver (n = 17) ALD (cirrhosis) (n = 10) Statistical significance
4 (40%) ns
0 (0%) P = 0.046
0 (0%) ns
0 (0%) ns
0 (0%) ns
0 (0%) ns
0 (0%) ns
0 (0%) ns
Table 5 Clinical, comorbidity and demographic factors for normal human liver cohort
PATIENT Gender Indication
resection
Pre-op
chemo
Regimen Comorbidity Diabetes Medication Background liver histology
1 Female Intrahepatic
cholangiocarcinoma
No Nil No Nil Bridging fibrosis and chronic
cholestasis
2 Male Colorectal mets No Nil No Nil Mild inflammation portal tracts
3 Male Extrahepatic
cholangiocarcinoma
No Nil No Nil Mild chronic inflammation portal
tracts and minimal steatosis
4 Female Colorectal mets Yes FOLFIRI and
Bevacizumab
Ischaemic heart disease;
hypertension; thoracic
outlet syndrome
No Aspirin; bendroflazide; fluoxetine; isosorbide
mononitrate; lansoprazole; simvastatin
Normal
5 Female Colorectal mets No Cleft palate; malnutrition No Aspirin; ferrous fumarate Normal
6 Female Colorectal mets Yes FOLFOX and
Cetuximab
Nil No Nil Mild to moderate macrovesicular
steatosis; degree of nodular
regenerative hyperplasia
7 Male Colorectal mets No Anxiety No Amitriptyline; propanolol; tamsulosin, loperamide Macrovesicular steatosis
8 Male Colorectal mets No FOLFIRI and
Bevacizumab
Hypertension No Amlodipine; ramipril Mild steatosis only
9 Female Colorectal mets No Nil No Omeprazole; temazepam Minimal macrovesicular steatosis
10 Female Colorectal mets No Capecitabine
and
Bevacizumab
Hypertension; hiatus
hernia
No Amlodipine; lansoprazole; pyridoxine; ramipril Unremarkable
11 Female Colorectal mets No Nil No Nil Unremarkable
12 Male Colorectal mets No Nil No Nil Normal
13 Male Colorectal mets No Nil No Nil Normal
14 Male HCC No Hypertension No Atenolol; candesartan; lercanidipine; simvastatin Moderate macrovesicular steatosis
- no fibrosis or steatohepatitis
15 Male HCC No Colorectal cancer No Aspirin Minimal macrovesicular steatosis
16 Male Colorectal mets No Ischaemic heart disease Ramipril; simvastatin; bisoprolol; aspirin Mild macrovesicular steatosis and
chronic inflammation of portal
tracts; no steatohepatitis or fibrosis
17 Male HCC No Breast cancer; Parkinson’s
disease; coeliac disease;
asthma
Betahistine; Calci-chew; Co-beneldopa; Co-careldopa;
ferrous fumarate; fluoxetine; seretide; ipratropium;
stalevo; omeprazole; oxytetracyline; ropinirole; salbutamol
Mild sinusoidal dilatation
otherwise normal
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Figure 2 DNA methylation at particular CG dinucleotides within the human PPARα gene promoter (A), PPARδ gene promoter (B), TGFβ1
exon 1 (C), collagen 1A1 intron 1 (D) and PDGFα gene promoter (E) in resected tissues from normal human liver donors or explanted
cirrhotic ALD livers was determined by pyrosequencing. The relative position and surrounding sequence of the differentially methylated CGs
are shown in the schematic drawing above the graphs. Differences are expressed as percentage of DNA methylation. Error bars represent mean
values ± standard error of the mean (SEM). *P < 0.05; **P < 0.01.
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fibrosis whereas PPARα (CpG3) and PPARδ (CpG2)
show considerably less methylation in the same group
(Figure 1A,B). We next compared cirrhotic ALD livers
with normal livers and found that the anti-fibrogenic
genes PPARα (all CpGs) and PPARδ (CpG3) had less
methylated DNA in normal livers, which is in line with
the results obtained from mild NAFLD. This poses the
interesting possibility that the methylation status of a
panel of genes may predict predisposition towards de-
velopment of liver fibrosis irrespective of the liver in-
jury, a very important factor in disease progression that
is currently impossible to predict. If a sufficient number
of genes harbour differential DNA methylation at par-
ticular CpGs, it may be possible to generate an algo-
rithm that can predict which patients are likely to
progress on to a severe phenotype versus those that will
remain fibrosis free despite the presence of liver injury.
As an example, the combination of higher methylation
at TGFβ1 (CpG2) and PDGFα (CpG3) with lower level
at PPARα (CpG3) and PPARδ (CpG2) may be sufficient
to stratify a patient into a rapid progressor cohort in need
of continued monitoring or specific therapy. However, the
numbers of patients included in our current study are not
sufficiently large to carry out a high-powered calculation.
If it proved possible to stratify patients into progressorsand non-progressors on the basis of DNA methylation fin-
gerprint at defined loci, such knowledge could be useful in
defining an appropriate clinical trial cohort, for testing of
anti-fibrotic drugs, for example. Such a cohort would be
more informative because the drug would be tested only
in those patients likely to progress onto fibrotic disease
with time.
In this study, we have chosen to compare ALD with
normal human liver and mild NAFLD with severe
NAFLD. To ensure that the chosen cohorts were compar-
able, ALD livers were always analysed with ‘normal’ livers
at the same time and on the same pyrosequencing ma-
chine, whereas mild NAFLD samples were analysed with
severe NAFLD on a separate machine. The two models,
however, were never analysed together at the same time.
As such, it is possible that variable factors may exist be-
tween the two cohorts that would alter absolute measured
values without amending the ratio between the compared
patient groups. Hence, the data have been reported separ-
ately for ALD and NAFLD cohorts (Figures 1 and 2).
A limitation of our study is that the data have been
obtained from cross-sectional analyses. It is possible that
DNA methylation status changes with disease progres-
sion and that the differences we observe are merely a re-
flection of the liver fibrosis grade rather than a useful
predictive or prognostic measure. This question can only
Figure 3 DNA methylation at CpG3 within the human PPARα gene promoter (A), CpG2 within PPARδ gene promoter (B), CpG2 within
TGFβ1 exon 1 (C) and CpG3 within PDGFα gene promoter (D) in a number of samples (ranging from 3 to 9) resected from normal human
liver from same donor was determined by pyrosequencing. Each patient is shown on x axis starting from youngest (furthest to the left) then
ranked by age up to the oldest on the right of the x axis. Female patients are shown in red and males in blue dots. Each dot represents the level
of DNA methylation in one sample of donor liver. Results are expressed as percentage of DNA methylation.
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disease in whom serial, longitudinal biopsies are col-
lected. In absence of such longitudinal data, we still have
to rely on cumulative knowledge from multiple studies,
which suggest that DNA methylation does play a role in
liver fibrosis as well as being an underpinning cause of
other associated comorbidities and complications.
It is also worth noting that NAFLD patients will have
on-going liver injury at the time of biopsy (unless they
have experienced substantial weight loss). In contrast,
ALD patients’ injury will turn on and off depending on
the extent of their drinking and so an additional factor
adding variability will be the pattern of alcohol intake,
despite the fact that most of the ALD patients used in
this study were cirrhotic. Incidentally, these issues will
also apply to the patients with ‘normal’ liver tissue; that
is, it is not clear whether any of them were occasional to
moderate drinkers? Thus, if DNA methylation is influ-
enced by grade of inflammation, then NAFLD patients
will have more stable patterns of disease than ALD pa-
tients. This would also offer a possible explanation for
the inability to truly replicate DNA methylation disease
patterns in ALD.
For the first time, we investigated the impact of ana-
tomical location, age and gender on DNA methylationstatus in the liver (Figure 3). Liver biopsy remains the gold
standard for histological assessment of liver disease sever-
ity, however, because an individual biopsy represents only
a very small part (around one 50,000th) of this complex
organ, gene methylation in a single liver biopsy may not
provide a good representation of methylation of that gene
throughout the organ. Furthermore, it is also not known
whether methylation patterns are influenced by gender
and age. If they were, this could complicate the use of
DNA methylation for diagnostic or prognostic purposes.
To answer these questions, we analysed a number of sam-
ples taken across distinctly separate regions of the liver,
spanning up to 25 cm in distance from the first to the last
sample within the same liver. We quantify methylation of
specific CpGs within PPARα (CpG3), PPARδ (CpG2),
TGFβ1 (CpG2) and PDGFα (CpG3), all of which we had
shown to be differentially methylated according to disease
state (Figures 1 and 2). We observed that intra-individual
variation in methylation for each CpG site was quite low
and methylation levels did not appear to be affected by
age or gender. This suggests that a single liver biopsy may
be adequate to provide quantitative estimates of DNA
methylation which are representative of the whole organ.
It is important to note that what is termed ‘normal’
human liver in this study clearly is not entirely normal,
Zeybel et al. Clinical Epigenetics  (2015) 7:25 Page 9 of 11rather these are normal margins collected from patients
undergoing major liver resections to remove primary or
secondary tumours. As such, the liver microenvironment
may be affected by the presence of tumour or indeed by
the treatments patients may have received, ranging from
chemotherapy as well as the drugs used to treat comor-
bidities. Although we cannot exclude the possibility that
these treatments may have influenced the methylation
pattern, uniformity of the data in Figure 3A-D suggest
that this is rather unlikely.
Our study supports previously published work that
shows DNA methylation is an important determinant
of NAFLD progression in patients [13], as well as of ac-
tivation of stellate cells and development of fibrosis in
animal models [19]. Changes in DNA methylation are
reported to accompany steatohepatitis in hepatitis C infec-
tion, with such changes preceding HCC emergence [20].
Importantly, previous evidence for interaction of the DNA
methylome with cellular phenotype provides a possibility
of therapeutic intervention in liver disease. This is based
on studies in rats where high methyl-donor diet causes
changes to DNA methylation in models of obesity [21],
while a methyl donor supplementation to a high-fat-high-
sucrose diet is able to reverse progression of liver damage
[22]. In addition, offspring of mice that were folate defi-
cient during pregnancy developed greater metabolic de-
rangement (30% higher intrahepatic lipid content) when
fed a high-fat diet [23]. Taken together, these studies,
along with our current data, provide a rationale for further
research into an epigenetic basis of chronic liver disease,
which may aid development of better diagnostic and prog-
nostic methods as well as therapeutic intervention.
Methods
Human subjects
Use of human tissue was approved by Newcastle and
North Tyneside Local Research Ethics Committee (ap-
proval number H10/H0906/41). All samples were col-
lected and used, subject to patient’s written consent.
Study design
Seventeen patients with biopsy-proven NAFLD and ten
patients with histologically proven cirrhotic ALD (eight
biopsies and two explant materials) from the Freeman
Hospital, Newcastle upon Tyne, UK, were included in
the study. NAFLD diagnosis was made with abnormal
serum transaminases, fatty liver on ultrasound and ab-
sence of excess alcohol intake (<30 g/day for males, <20
g/day for females), viral hepatitis (hepatitis B and C and
HIV), hereditary hemochromatosis, Wilson’s disease,
autoimmune hepatitis, α1 antitrypsin deficiency and
drug-induced liver injury. ALD diagnosis was made after
the exclusion of other diagnoses as above but including
a history of alcohol excess defined as >60 g/day formales and >40 g/day for females. Nineteen non-fibrotic
liver tissue samples were obtained from patients who
underwent hepatic resections for colorectal cancer liver
metastasis. Clinical and laboratory data were collected at
the time of biopsy, resection or transplant including basic
anthropometrics so that BMI could be calculated. Patients
were identified as having type 2 diabetes (T2DM) if they
were receiving dietary, oral hypoglycaemic drug or insulin
treatment for diabetes or had fasting blood glucose >7.0
mmol/L or glucose >11.1 mmol/L following an oral glu-
cose tolerance test. Percutaneous liver biopsies were per-
formed using a Menghini needle or an 18G BioPince liver
biopsy system (Medical Devices Technologies, Gainesville,
FL, USA). Liver specimens were assessed by two experi-
enced hepatopathologists. Histological scoring was per-
formed according to the NIH NAFLD Clinical Research
Network criteria for NAFLD biopsies [24]. Mild disease
was defined as fibrosis stage 0 to stage 2, whilst severe dis-
ease was defined as fibrosis stage 3 to stage 4. ALD liver
sections were reviewed, classified and staged by an expert
clinical pathologist according to criteria published previ-
ously [25]. Histological sections were stained with haema-
toxylin and eosin and sirius red.
Genomic DNA extraction
DNA was extracted from formalin-fixed paraffin-embedded
(FFPE) liver biopsy specimens in the ALD and NAFLD co-
hort. Two specimens in the ALD cohort were extracted
from FFPE cirrhotic explant livers and the rest were needle
biopsies. Non-fibrotic liver samples were selected >5 cm
away from tumour margin in resected liver tissue. Three
curls with the thickness of 10 μm were cut from each par-
affin block. FFPE tissues were dewaxed by treating with
Clearene (Leica Biosystems, Wetzlar, Germany) and seri-
ally dehydrated in 100% then 70% ethanol. DNA was ex-
tracted using QIAamp DNA Micro Kit (Qiagen, Germany,
catalogue no: 56304). Tissues were lysed at 56°C over-
night, treated at 70°C for 30 min to remove crosslinks that
were formed by formalin, and the lysate was processed
and transferred to spin columns as per manufacturer’s in-
structions. Genomic DNA was quantified using NanoDrop
(Thermo Scientific, Waltham, MA, USA, Nanodrop 2000,
UV-vis spectrophotometer).
Bisulfite modification
Sodium bisulfite conversion was performed using EZ
DNA Methylation Gold TM Kit (Zymo Research, Irvine,
CA, USA). A 2 μg of genomic DNA was bisulphite
modified by incubating at 98°C for 10 min and 64°C for
2 h and 30 min. Product was transferred into columns;
desulphonated and washed according to manufacturer’s
protocol and eluted in 10 μl of elution buffer. A 2 μl of
bisulphite modified genomic DNA (400 ng) was ampli-
fied in a PCR mix containing 2 μl of forward and reverse
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Germany, catalogue no: 203445) and 10.5 μl of water.
Amplification of DNA was performed in a thermocycler
according to the following PCR conditions: one cycle at
95°C for 6 min, followed by 40 cycles of 95°C for 30 s,
annealing temperature of 55°C to 59°C (depending on
primer pair) for 30 s and 72°C for 30 s, followed by one
cycle at 72°C for 30 s.
Pyrosequencing
Methylation of specific cytosines within CpG dinucleo-
tides was quantified by pyrosequencing using a Pyromark
Q96 MD (Qiagen) instrument. PCR and sequencing
primers were obtained from predesigned assays;
HsCOL1A101_PM PyroMark CpG assay (Qiagen,
PM00065821), HsTGFB101_PM PyroMark CpG assay
(Qiagen, PM00073913), HsPPARA01PM PyroMark
CpG assay (Qiagen, PM00082635), HsAC147651.101
PM PyroMark CpG assay (Qiagen, PM00031745) and
HsPPARD01PM PyroMark CpG assay (Qiagen,
PM00121310). A 10 μl of biotin-labelled PCR product
was used in each well and combined by streptavidin-
coated sepharose beads, washed in 70% ethanol, dena-
tured in 0.01% sodium azide and washed in a wash buffer
(Qiagen, PyroMark Wash Buffer, 979008). Sequencing
primers were annealed to DNA product at 80°C. Samples
were run in duplicate. Assay efficiency was validated by
unmethylated and methylated DNA (Qiagen, EpiTect
PCR Control DNA Set, 59695). CpG methylation data was
analysed by Pyro Q-CpG software 1.0.6. Levels of DNA
methylation have been measured independently in the
compared cohorts. DNA methylation was measured in
ALD livers alongside ‘normal’ livers within the same run
using the same pyrosequencing machine to ensure that ab-
solute values of DNA methylation measured were always
the same for the specified cohort. DNA methylation in the
mild and severe NAFLD samples were also analysed in the
same run using a different pyrosequencing machine. The
two models were never analysed together at the same time.
Statistical analysis
Data are expressed as means ± SEM. GraphPad Instat was
used to perform Mann-Whitney U test or chi-square test
where *P <0.05, **P <0.01 or ***P <0.001 were considered
significant.
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